Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?

Andreea, Munteanu Madalina; Surabhi, Swarnkar; Popescu, R.; Ciobotaru, Lucia; Nicolae, Camelia; Emil, Tufanoiu; Tiberiu, Nanea Ioan

doi:10.3390/medicina59040742

Cited by 5 publications

(6 citation statements)

References 86 publications

(123 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These drugs also help lower blood pressure, promote weight loss, improve arterial function, and reduce inflammation. Another conducted by Chesterman et al [12] supports the findings of Andreea et al [11] and reveals that SGLT2 inhibitors have emerged as a valuable therapeutic option for the treatment of cardiovascular disorders [41]. The clinical trials and real-world evidence show that these medications can reduce the risk of major adverse cardiovascular events, including heart attacks, strokes, and cardiovascular death.…”

Section: Comparison With the Existing Literaturementioning

confidence: 68%

“…The study conducted by Andreea et al [ 11 ] revealed that the SGLT2 inhibitors offer unexpected benefits beyond their glucose-lowering effects. The findings of these drugs indicate that these medications provide significant cardiovascular benefits, including reducing the risk of major adverse cardiovascular events, such as heart attacks, strokes, cardiovascular death, etc.…”

Section: Reviewmentioning

confidence: 99%

“…The sodium-glucose cotransporter 2 (SGLT2) inhibitor drugs have emerged as a prospective therapeutic choice for the treatment of cardiovascular disorders [ 11 , 12 ]. Originally developed as SGLT2 inhibitors for the treatment of type 2 diabetes mellitus, these drugs are now being used for cardiovascular disorders as well, owing to their glucose-lowering effects [ 13 - 15 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors to Decrease the Risk of Cardiovascular Diseases: A Systematic Review

Moparthi,

Al Rushaidi,

Muddam

et al. 2023

Cureus

View full text Add to dashboard Cite

Cardiovascular disorders are one of the most frequent causes of death in people throughout the world. These disorders can account for the deaths of 31% of people worldwide. This systematic review examines the effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors in lowering the likelihood of cardiovascular diseases. The study aimed to evaluate various types of research, including randomized controlled trials and observational studies, to analyze how SGLT2 inhibitors impact cardiovascular disorders and establish evidence-based recommendations for clinical practice. The data in this research study were collected from 19 relevant published research articles. The key findings emphasized the potential advantages of SGLT2 inhibitors in reducing major cardiovascular disorders, such as myocardial infarction and stroke. Nonetheless, the study had certain limitations, including reliance on existing literature, exclusion of articles published prior to 2018, and restriction to English-language studies. Despite these limitations, this study contributed significantly to understanding the role of SGLT2 inhibitors in decreasing cardiovascular risk.

show abstract

Section: Comparison With the Existing Literaturementioning

confidence: 68%

Section: Reviewmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors to Decrease the Risk of Cardiovascular Diseases: A Systematic Review

Moparthi,

Al Rushaidi,

Muddam

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…The approval of these novel glucose-lowering agents began in 2013 and since then, six SGLT2 inhibitors have been approved for the treatment of T2DM by the FDA and EMA: empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, bexagliflozin, and sotagliflozin [31]. Their cardioprotective mechanisms can be explained by an increase in distal tubular sodium load, inhibiting the renin-angiotensin system (RAS) and reducing preload (natriuresis and diuresis) and afterload (arterial vasodilatation).…”

Section: Discussionmentioning

confidence: 99%

Fournier’s Gangrene as an Adverse Event Following Treatment with Sodium Glucose Cotransporter 2 Inhibitors

Suciu,

Greluș,

Cozlac

et al. 2024

Medicina

View full text Add to dashboard Cite

We present the case of a 51-year-old male with known congestive heart failure and acute myocarditis who presented to the emergency department (ED) with swollen testicles and urinary symptoms two weeks after the initiation of sodium glucose cotransporter 2 (SGLT2) inhibitor treatment. Abdominal and pelvic computed tomography (CT) scan was consistent with the diagnosis of Fournier’s gangrene (FG). Intravenous antibiotics were administered and surgical exploratory intervention and excision of necrotic tissue were performed, stopping the evolution of necrotizing fasciitis. FG, a reported adverse event, may rarely occur when SGLT2 inhibitors are administered in patients with diabetes. To our knowledge, there have been no reported cases of FG in Romania since SLGT2 inhibitors were approved. The distinguishing feature of this case is that the patient was not diabetic, which emphasizes that patients without diabetes who are treated for heart failure with SGLT2 inhibitors may also be at risk of developing genitourinary infections. The association of predisposing factors may have contributed to the development of FG in this case and even though the benefits of SGLT2 inhibitors outweigh the risks, serious adverse events need to be voluntarily reported in order to intervene promptly, verify the relationship, and minimize the risk of bias.

show abstract

“…Nevertheless, the positive impact of GLP-1 drugs on weight loss and appetite control is confirmed, enabling obesity treatment to be more effective. Due to the adverse effects of obesity on psoriasis and PsA, these drugs could indirectly improve both conditions [ 84 ]. Thus, GLP-1 analogs may be a suitable option for obese patients with PsA due to their ability to diminish low-grade inflammation caused by excessive fat tissue.…”

Section: Diabetes Mellitus Type 2 Treatment In Psa Patientsmentioning

confidence: 99%

Molecular Background and Clinical Implications of Glucose Disorders in Patients with Psoriatic Arthritis

Grygiel-Górniak,

Skoczek

2023

JCM

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease characterized by joint and entheses involvement. This condition is often associated with an increased prevalence of obesity, encompassing more than one-third of all patients. Given the presence of metabolic disorders, it becomes crucial to enhance clinical oversight of metabolic parameters. An early diagnosis of glucose irregularities in PsA allows for the assessment of an effective treatment strategy. The approach proves valuable in preventing the development of insulin resistance (IR) or diabetes mellitus type 2 (DMt2). Similar pathways characterize the pathomechanism of PsA and DMt2, offering an innovative perspective on treatment management. The cytokines and adipokines synthesized in the course of PsA significantly impact the development process of IR and DMt2 in different mechanisms of action. Conversely, glucose disorders influence the activity of PsA and therapy outcomes. Given the chronic inflammatory background shared by PsA, obesity, and DMt2, it is evident that inadequate management of any of the mentioned conditions can exacerbate the others. Thus, when PsA coincides with DMt2, a comprehensive multidimensional approach is necessary. This includes an effective immunosuppressive regimen complemented by appropriate anti-diabetic and insulin therapies. Moreover, often overlooked recommendations concerning overall well-being and lifestyle adjustments hold significance. This manuscript explores the connections and the relationship between the molecular background of PsA and glucose disorders. It provides a detailed exposition of specific therapeutic approaches for both conditions.

show abstract

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?

Cited by 5 publications

References 86 publications

Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors to Decrease the Risk of Cardiovascular Diseases: A Systematic Review

Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors to Decrease the Risk of Cardiovascular Diseases: A Systematic Review

Fournier’s Gangrene as an Adverse Event Following Treatment with Sodium Glucose Cotransporter 2 Inhibitors

Molecular Background and Clinical Implications of Glucose Disorders in Patients with Psoriatic Arthritis

Contact Info

Product

Resources

About